semaj83/ctmatch_classification huggingface dataset:
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Carcinoma, Renal Cell Locally advanced or metastatic, histologically proven clear cell or papillary cell renal carcinoma. 2. Primary tumour surgically removed. 3. Progressive disease 4. At least four weeks from any previous therapy for renal cancer. 5. Fit for first or second line immunotherapy with subcutaneous low dose IL-2 6. Measurable disease 7. Aged 18 years or more. 8. Patients must comply with the following Karnofsky score ≥ 80% Corrected calcium ≥ 10 g/dL (2.5 mmols/L) 9. Clinically immunocompetent 10. Free of clinically apparent autoimmune disease. 11. Haemoglobin ≥ 9 g/dL, total white cell count ≥ 3 x 10^9/L and lymphocyte count ≥ 1 x 10^9/dL 12. Serum creatinine up to 1.5 times upper limit of normal. 13. Bilirubin ≤ 2 mg% and an SGPT of ≤ 4 times the upper limit of normal. 14. Able to give written informed consent and to comply with the protocol. 15. Women must be either post menopausal, or rendered surgically sterile or, if of child bearing potential, must have been practising a reliable form of contraception (oral contraception + a barrier method) for at least three months prior to the first dose of TroVax® and must continue while they are being treated with TroVax®. Men must practise a reliable form of contraception while they are being treated with TroVax®. 16. No acute changes on 12-lead electrocardiogram (ECG) 17. Ejection fraction on echocardiogram ≥ 45%  Previous immunotherapy with any schedule of IL-2. 2. Intercurrent serious infections within the 28 days prior to entry into the trial. 3. Life threatening illness unrelated to cancer. 4. Cerebral metastases on MRI scan. 5. History of allergic response to previous vaccinia vaccinations. 6. Participation in any other clinical trial of a licensed or unlicensed drug within the previous 30 days or during the course of this trial. 7. Previous malignancies within the last 10 years other than successfully treated squamous carcinoma of the skin or in situ carcinoma of the cervix treated with cone biopsy. 8. Previous history of major psychiatric disorder requiring hospitalisation or any current psychiatric disorder that would impede the patient's ability to provide informed consent or to comply with the protocol. 9. Known allergy to egg proteins 10. Chronic oral corticosteroid use unless prescribed as replacement therapy in the case of adrenal insufficiency. 11. Known to test positive for HIV or hepatitis B or C 12. Known hypersensitivity to neomycin 13. Pregnancy or lactation
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Thrombocytopenia Small for Gestational Age (SGA) Preeclampsia Infants who are less than 34 weeks gestation Infants born to mothers with preeclampsia Infants who are born small for gestational age whose mother did not have preeclampsia  Infants who are greater than 34 weeks gestation Infants with known congenital anomalies or known congenital infections
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  HIV DNA and relevant clinical data from properly consented WIHS subjects (maximum estimated at 3500) will be provided to our lab for genotyping and analysis  No available subjects will be excluded
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  ALS Cases were eligible to participate in the original study if (1) they had received a diagnosis of ALS within 2 years; (2) they lived in New England at least half the year; (3) they spoke English; (4) they were mentally and physically able to participate. The same were used for controls  Potential controls were excluded if they had a physician diagnosis of a neurodegenerative disease, polio, post-polio syndrome, or nondiabetic neuropathy. Pregnant women were excluded from both case and control groups
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 15.0-19.0,  Teen Pregnancy The following will determine for the study: 1. African American and Latino primiparous pregnant or newly parenting (0-6 weeks); 2. Age 15-18 years inclusive; and 3. Teens who are 19 years old if they have not graduated from high school  Non-English speaking; 2. Any serious medical condition or disability that would interfere with the participant responding adequately to evaluation measures; 3. Obvious cognitive impairment that interferes in participating in informed consent; 4. Incarceration at enrollment or during the study
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 30.0-50.0,  Obesity Both genders, BMI ≥ 30 kg/m² and <40 kg/m²  Known abnormal thyroid hormone levels, or high thyroid stimulating hormone (TSH) level
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Severe Hepatic Veno-Occlusive Disease Clinical diagnosis of VOD, defined by jaundice (bilirubin >/= 2 mg/dL) and at least 2 of the following clinical findings, by Day+21 post stem cell transplant: ascites; weight gain >/= 5% above baseline weight; hepatomegaly Severe VOD, defined as VOD with multi-organ failure, i.e., presence of one or both of the following, by Day+28 post stem cell transplant: renal or pulmonary dysfunction Provide voluntary written informed consent  Pre-existing (prior to SCT) cirrhosis An alternative diagnosis for weight gain, ascites and jaundice Graft-versus-host disease (GVHD) grade B or higher involving liver or gut or grade C or higher involving skin Prior solid organ transplant Dependent on dialysis prior to and/or at the time of SCT Dependent on oxygen supplementation prior to SCT Significant acute bleeding or hemodynamic instability Requirement for the use of any medications that increase risk of hemorrhage will be excluded from the treatment group
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Polycystic Ovary Syndrome Probands who meet the following will be enrolled: Menses < 6 per year without confounding meds Not taking confounding medications at the time of hormone analysis, willing to be off confounding medications for required washout period, or able to provide documentation of hyperandrogenemia (without hyperprolactinemia or evidence of non-classical adrenal hyperplasia) with past laboratory tests during a time when not taking confounding medications Total Testosterone >58 ng/dl or bioavailable testosterone >15 ng/dl Prolactin <25 ng/ml Baseline 17-OHP <3 ng/ml (and stimulated 17-OHP <10 ng/ml if subject is studied on-site) Control women who meet the following will be enrolled: History of completely regular menstrual cycles. No history of hirsutism or alopecia. Control women will have a blood sample obtained 3-6 months after they have stopped lactating and resumed regular menses to ensure that they have normal T, uT and DHEAS levels. Any pregnant woman who develops gestational diabetes will be excluded from the analysis. To disorders associated with insulin resistance, control subjects will have no personal history of hypertension or hypertriglyceridemia and no first-degree relative with Type 2 DM  history of gestational diabetes mellitus, eclampsia, pre-eclampsia or any medical disorders complicating their pregnancies
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Hepatitis B Subjects were to have completed primary vaccination course. A male or female > = 15 years of age at the time of the first vaccination Written informed consent obtained from the subject/ from the parents or guardians of the subject If the subject was a female, she was of non-childbearing potential or, if of childbearing potential, she was to be abstinent or use adequate contraceptive precautions for one month prior to enrollment and up to two months after the last vaccination  Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period Pregnant or lactating female
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Subclinical Hypothyroidism Hypothyroxinemia Pregnancy Subclinical Hypothyroidism as defined by an elevated TSH (≥ 3.00 mU/L) and a free-T4 in the normal range (i.e. 0.86 to 1.90 ng/dL) or Hypothyroxinemia as defined by a TSH in the normal range (0.08 to 2.99 micrometers (mU)/L) and a low free-T4 (<0.86 ng/dL) Singleton Pregnancy Gestational age at randomization between 8 weeks 0 days and 20 weeks 6 days  Major fetal anomaly or demise 2. Planned termination of the pregnancy 3. History of thyroid cancer or current thyroid disease requiring medication 4. Diabetes, on medication (insulin, glyburide) 5. Collagen vascular disease (autoimmune disease), such as lupus, scleroderma and polymyalgia rheumatica, on medication 6. Receiving anticoagulant therapy 7. Depression, currently on treatment with tricyclics or selective serotonin reuptake inhibitors (SSRIs) 8. Other known serious maternal medical complications including: 1. Chronic hypertension requiring antihypertensive medication (including diuretics) 2. Epilepsy or other seizure disorder, on medication 3. Active or chronic liver disease (acute hepatitis, chronic active hepatitis) with persistently abnormal liver enzymes 4. Cancer (including melanoma but excluding other skin cancers) 5. Heart disease (tachyrhythmia, class II or greater heart disease or on heart medication). Mitral valve prolapse without arrhythmia is not an exclusion. 6. Asthma, on oral corticosteroids 9. Known illicit drug or alcohol abuse during current pregnancy 10. Delivery at a non-network hospital 11. Participation in another intervention study that influences maternal and fetal morbidity and mortality, or participation in this trial in a previous pregnancy 12. Unwilling or unable to commit to 5 year follow-up of the infant
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Chronic Kidney Disease End Stage Renal Disease GFR by the MDRD estimate < 30ml/minute/1.73m2 or on hemodialysis  Body mass index greater than 35 kg/m2, or morbid obesity Uncontrolled hypothyroidism, defined as an elevated serum thyroid stimulating hormone (THS) and a free serum thyroxine (T4) less than the lower limit of normal, when tested at baseline (Patients requiring thyroid replacement during the study may continue.) Uncontrolled hyperthyroidism, defined as a TSH less than the lower limit of normal and an elevated free T4, when tested at baseline Hemoglobin <10 Gm/dl Elevated serum transaminases (>2.0 times the upper limit of normal at baseline) Diabetes with one of more of the following: 1. Poorly controlled diabetes as defined by a HbA1C > 7.0% at baseline) 2. Proliferative diabetic retinopathy [To participate in this study, diabetic patients will need to have had a dilated ophthalmology exam within 12 months of enrollment. Individuals who already have extensive background retinopathy will need to have a dilated ophthalmology exam within the 3 months of enrollment. Patients with pre-proliferative or proliferative retinopathy will be excluded]. 3. Unwilling or unable to check blood glucose at home at least daily Currently receiving a systemic corticosteroid dose of >10 mg prednisone (or equivalent), or patient has received, for a duration > 30 days in the previous 6 months (i.e., prior to signing the informed consent form), a systemic corticosteroid dose of > 10 mg prednisone (or equivalent). (The previous use, or current use, of a topical or inhaled corticosteroid is allowed.) Currently taking or previously on an anabolic steroid or growth hormone at any dose, or for any duration, during the 12 months prior to study entry Significant end-organ disease, other than kidney disease, which, in the opinion of the investigator may pose an added risk to the patient, confound the study results, or impair the patient's ability to complete the trial Any of the following disorders within 6 months prior to baseline: 1. Acute coronary syndrome (e.g., myocardial infarction or unstable angina) 2. Coronary artery intervention (e.g., coronary bypass graft [CABG], percutaneous transluminal coronary angioplasty [PTCA]). 3. Stroke or transient ischemic neurological disorder (e.g. transient ischemic attack [TIA])
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 16.0-80.0,  Head and Neck Cancer Histologically confirmed differentiated thyroid cancer T1-T3, Nx, N0, N1, M0 disease Has undergone one or two-stage total thyroidectomy with or without lymph node dissection All known tumor resected (R0) Requires radioiodine remnant ablation Does not require mandatory recombinant thyroid-stimulating hormone No Hurthle cell carcinoma or aggressive variants, including any of the following Tall cell, insular, poorly differentiated disease with diffuse sclerosing Anaplastic or medullary carcinoma
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 16.0-45.0,  Weight Gain Subject (or legal guardian) is capable and willing to provide signed written informed consent Male or female subjects 16 to 45 years of age Body mass index in the range of 18.5 to 35 kg/m2 Diagnosed as having schizophrenia, schizoaffective disorder, schizophreniform disorder or a psychosis disorder that is not otherwise specified (NOS) according to the DSM-IV criteria Maximum of 6 weeks cumulative lifetime exposure to risperidone, OR maximum of 3 weeks cumulative lifetime exposure to any other antipsychotic medication Designated by the managing physician to be appropriate for treatment with olanzapine; and If female: is non-lactating, has a negative blood serum pregnancy test result, and does not plan on becoming pregnant during the study, or is not of childbearing potential (hysterectomy or tubal ligation at least 6 months prior to randomization or post-menopausal for 1 year); if of childbearing potential (including peri-menopausal women who have had a menstrual period within one year), must practice and be willing to continue to practice appropriate birth control (such as implants, injectables, oral contraceptives, intrauterine contraceptive devices, sexual abstinence, tubal ligation, or a vasectomized partner) during the entire study duration  Has obesity of known endocrine origin (e.g., Cushing's disease, Addison's disease, hypothalamic tumor) Has a medical history (e.g., morbid childhood obesity) and/or physical characteristics (e.g., polydactyly) suggestive of genetic obesity (e.g., ob/ob genotype) or syndromatic obesity (e.g., Prader-Willi syndrome, Bardet Biedl syndrome) Previous surgical procedures for weight loss Has had liposuction within 1 year before screening or is planning to have liposuction during the study Has a clinically significant history or presence of any of the following conditions Active or past history of cardiovascular or cerebrovascular disease including unstable angina, myocardial infarction, transient ischemic attacks/stroke, clinically significant arrhythmia, congestive heart failure, or cardiac valve abnormalities Type 1 diabetes mellitus Type 2 diabetes mellitus with treatment other than metformin monotherapy and/or diet with HbA1c >8% Severe type 2 diabetes with history of ketoacidosis or diabetic ulcers, or presence of retinopathy, neuropathy, or nephropathy Renal insufficiency defined as a serum creatinine >=1.5 mg/dL (133 µmol/L) at screening
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 14.0-61.0,  Graves Disease Graves disease  Anticoagulant usage Previous thyroid operation Refused to participate in this study
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Differentiated Thyroid Carcinoma Hiostologically proved DTC (M0)  Preoperative metastasis
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Secondary Hyperparathyroidism Age older than 18 yrs On hemodialysis for at least 3 months (thrice weekly) iPTH >300pg/ml or histological evidence of secondary hyperparathyroidism Calcium > 8.1 mg/dl  Unstable clinical condition